Search

everythinglearnresearchcommunity

for

Search:↓

Users discuss using pyrilutamide for hair loss, seeking alternatives to 5AR inhibitors. They mention using minoxidil, ketoconazole shampoo, and RU58841.

The conversation is about personal experiences with Anagenic Pyrilutamid for hair loss and what carriers people use with it. No specific treatments or outcomes are mentioned.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

The user discusses using dutasteride to stop hair loss and bimatoprost for regrowth. They plan to use VEGF with hydrogels for potentially permanent hair follicle improvement and suggest PRP as an alternative.

Amplifica has not provided updates on SCUBE3 and AMP-303, raising concerns about their trial outcomes. Users also mention other treatments like Minoxidil, finasteride, RU58841, PP405, and ET-03.

The user is using finasteride, HGH, GHK-CU, BPC-157, KPV, biotin/collagen/keratin vitamins, ketoconazole shampoo, and low-dose naltrexone to address hair loss, avoiding minoxidil due to past shedding experiences. Adenosine is discussed as a potential alternative to minoxidil, though it is noted to be expensive and hard to find.

The user is addressing hair loss with finasteride, dutasteride, oral and topical minoxidil, dermarolling, and shampoos. They are considering adding essential oils to improve circulation.

PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

The conversation discusses the effectiveness of Spartan Root Activator shampoo for hair loss. It mentions treatments like Minoxidil, finasteride, and RU58841.

User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.

12 companies having drugs or therapies in clinical trials during 2023, with various molecules and phases of trial; the probability that some may fail; and progress being made in the field.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

User tried oral finasteride, topical finasteride, topical dutasteride, and RU58841 but experienced side effects. They discuss upcoming treatments like clascoterone, pyrilutamide, gt20029, and KY19382 as potential options.

Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.

A treatment containing Wnt and Follistatin was found to be safe and effective for hair regrowth in a Phase 1 clinical trial. Specific treatments discussed include Minoxidil, Finasteride, and RU58841.

The conversation discusses new research on hair growth by Dr. Maksim Plikus, with a call for clinical trials to begin. No specific treatments are mentioned.

The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.

Follistatin, known for inhibiting myostatin and promoting muscle growth in mice, is being discussed as a potential treatment for hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

Calecim (PTT-6) Advanced Hair System is a 6-week hair restoration product using stem cell-derived ingredients to stimulate hair growth. Users are skeptical, calling it overpriced and ineffective, suggesting alternatives like LLLT devices or PRP treatments.

The conversation is about the effectiveness of peptides for hair loss and the user considering using GHK-Cu, CJC-1295, and BPC-157 for treatment.

Rosemary-lavender oil can stimulate hair growth compared to a placebo. Some users combine it with treatments like dutasteride, minoxidil, and RU58841.

Red light therapy with dual wavelengths (650nm and 850nm) can stimulate hair regrowth without DHT blockers. Consistent use of a panel with these wavelengths has shown positive results in hair regrowth.

PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.

The conversation discusses hair loss treatments, with the original poster considering joining a clinical trial for setipiprant after experiencing side effects from finasteride and disinterest in minoxidil. Some users express skepticism about setipiprant's effectiveness, while others encourage participation in the trial for potential benefits.

The user has been using oral minoxidil and dutasteride for hair loss without success and is considering adding topical 17α-estradiol, Pyrilutamide, Clascoterone, or cetirizine. They have confirmed low serum DHT levels and are exploring additional treatments due to genetic sensitivity to DHT and prostaglandin D2.

Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.

A user plans to create a DIY topical treatment for hair loss using Rapamycin, possibly combined with alpha-ketoglutaric acid (a-KG). They discuss the concentration and formulation process for Rapamycin, considering safety and skin penetration, and intend to apply it every other day to the scalp.

Combining therapies like scyllo-inositol, alpha-ketoglutarate, and autophagy-inducing supplements may enhance hair growth and prevent hair loss. Reporting individual results can accelerate progress in hair loss treatments.

Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.